Dr. Philip Castle is director of the Division of Cancer Prevention at the National Cancer Institute (NCI), overseeing research in cancer prevention, early detection, screening, and the management of symptoms and toxicities in cancer patients. He is also a senior investigator with NCI’s Division of Cancer Epidemiology and Genetics (DCEG), focused on new technologies for the prevention of cancer.
Dr. Castle received his public health training at the NCI Cancer Prevention Fellowship Program from 1999 to 2002. He also earned a PhD in biophysics in 1995 and a master’s in public health in 2000, both from The Johns Hopkins University.
Prior to his current role, Dr. Castle was a tenured professor in the Department of Epidemiology and Population Health at Albert Einstein College, and a visiting professor at institutions in Singapore, China, and Australia. He also served as chief scientific officer of the American Society for Clinical Pathology and worked at DCEG as a fellow, investigator, and then senior investigator.
Dr. Castle has been a principal investigator for more than 15 years, leading several large NCI molecular and clinical epidemiologic research studies in the U.S. and internationally. Dr. Castle has co-authored more than 400 published articles on HPV and cervical and anogenital cancers, as well as other cancer-related research. He was named NCI Cancer Prevention Fellowship Distinguished Alumnus in 2017 and was honored with the Arthur S. Flemming Award for Government Service in Applied Science, Engineering, and Mathematics in 2010.